Combination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-08-31

Study Completion Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Drugs used in chemotherapy, such as bleomycin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving combination chemotherapy together with pegfilgrastim may kill more tumor cells.

PURPOSE: This phase II trial is studying the side effects and how well giving combination chemotherapy together with pegfilgrastim works in treating men with metastatic germ cell tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Combination Chemotherapy in Treating Male Patients With Germ Cell Tumors

NCT00301782

Extragonadal Germ Cell Tumor Teratoma Testicular Germ Cell Tumor

COMPLETED PHASE2

Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer

NCT00003941

Mediastinal Cancer Metastatic Cancer Testicular Germ Cell Tumor

COMPLETED PHASE3

Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours

NCT01726374

Stage I Testicular Non-Seminomatous Germ Cell Tumor

COMPLETED PHASE3

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

NCT02582697

Germ Cell Tumor

RECRUITING PHASE3

Combination Chemotherapy in Treating Men With Germ Cell Cancer

NCT00003643

Extragonadal Germ Cell Tumor Teratoma Testicular Germ Cell Tumor

UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* Determine the feasibility of accelerated treatment comprising bleomycin, etoposide, cisplatin, and pegfilgrastim in men with metastatic germ cell tumors.
* Determine the toxicity of this regimen (particularly with respect to renal, pulmonary, and neurological function) in these patients.

Secondary

* Determine the response rate in patients treated with this regimen.
* Determine the progression-free survival of patients treated with this regimen.

OUTLINE: This is a non-randomized, pilot study.

Patients receive etoposide IV on days 1-3, cisplatin IV on days 1 and 2, and bleomycin IV over 2 hours on days 2, 6, and 10. Patients also receive pegfilgrastim subcutaneously on day 4. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 2 years.

PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Extragonadal Germ Cell Tumor Teratoma Testicular Germ Cell Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bleomycin sulfate

Intervention Type BIOLOGICAL

pegfilgrastim

Intervention Type BIOLOGICAL

cisplatin

Intervention Type DRUG

etoposide

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Patients must fulfill all of the following criteria for 1 of the following diagnoses:

* Nonseminoma germ cell tumor (intermediate risk)

* Testis or retroperitoneal primary
* Abnormal markers (alpha fetoprotein \[AFP\] \> 1,000 and \< 10,000 ng/mL, human chorionic gonadotropin \[HCG\] \> 5,000 and \< 50,000 IU/L, lactate dehydrogenase \[LDH\] \> 1.5 times and \< 10 times upper limit of normal \[ULN\])
* No liver, bone, brain, or other nonpulmonary visceral metastasis
* Histologic confirmation is not required if AFP or HCG are grossly elevated
* Nonseminoma germ cell tumor (poor prognosis) meeting 1 of the following criteria:

* Mediastinal primary
* Nonpulmonary visceral metastases
* Poor markers (AFP \> 10,000 ng/mL, HCG \> 50,000 IU/L, LDH \> 10 times ULN)
* Histologic confirmation not required if AFP or HCG are grossly elevated
* Seminoma (intermediate prognosis)

* Histological confirmation is required
* Any primary site
* Nonpulmonary visceral metastases must be present
* Normal AFP
* Any HCG
* Any LDH
* Surveillance relapse

* Must fulfill appropriate criteria above according to initial histology

PATIENT CHARACTERISTICS:

* Neutrophil count ≥ 1,000/mm³
* Platelet count ≥ 100,000/mm³
* Must have adequate renal function (creatinine clearance ≥ 60 mL/min)
* No prior malignancy except basal cell carcinoma

PRIOR CONCURRENT THERAPY:

* No prior chemotherapy or radiotherapy

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No